Project Details
Description
Hepatitis B virus (HBV) is a major cause of chronic viral hepatitis that increases dramatically the risk of liver
cancer and other end-stage liver diseases such as cirrhosis. The major obstacle to curing chronic HBV
infection is the persistence of the viral nuclear episome, the covalently closed circular (CCC) DNA, which is
derived from the relaxed circular (RC) DNA contained within the viral nucleocapsid. Moreover, the inability
of mouse hepatocytes to support CCC DNA formation remains a major hurdle in the development of an
immuno-competent mouse model for HBV infection. This MERIT Award Extension application builds on,
and extends, our current work on the disassembly of viral nucleocapsids (uncoating), which releases the
RC DNA into the host cell nucleus, a prerequisite step for nuclear CCC DNA formation but also exposing
RC DNA for potential degradation or triggering of host cell DNA sensing and immune responses. The main
goal of the Extension is to better understand viral and host control of HBV CCC DNA formation and
infection. Four Specific Aims are proposed. Aim 1 will elucidate the deficiencies in mouse hepatocytes for
HBV infection. Aim 2 will develop cell-free systems for nucleocapsid uncoating and CCC DNA formation.
Aim 3 will define the late HBV entry events controlled by the viral capsid and host factors. Aim 4 will assess
the role of DNA sensing in HBV infection.
RELEVANCE (See instructions):
The hepatitis B virus (HBV) is a global cause of chronic liver diseases, including liver cirrhosis and cancer.
We propose to elucidate the mechanisms of, and viral and host factors involved in, the viral trafficking
events during infection and the disassembly of HBV nucleocapsid, which are essential but poorly
understood steps in viral replication and contribute to the host tropism of HBV. These studies will bring
novel insights into HBV infection and nucleocapsid disassembly and facilitate ongoing efforts to develop
novel antiviral agents targeted at these processes as well as mouse models of HBV infection.
Status | Active |
---|---|
Effective start/end date | 9/14/18 → 8/31/25 |
Funding
- National Institute of Allergy and Infectious Diseases: $380,601.00
- National Institute of Allergy and Infectious Diseases: $373,044.00
- National Institute of Allergy and Infectious Diseases: $483,339.00
- National Institute of Allergy and Infectious Diseases: $494,893.00
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.